Clinical study of zoledronic acid in the treatment of bone metastasis in patients with lung cancer
Objective To study and analyze the clinical effect of zoledronic acid in the treatment of bone metastasis in patients with lung cancer.Methods 50 cases of lung cancer patients with bone metastasis from January 2015 to December 2016 in our hospital were selected and randomLy divided into two groups, the control group and the experimental group, with 25 patients in each group.The control group was treated with pamidronate intravenous drug treatment, patients in the experimental group of zoledronic acid monotherapy in the treatment of.After treatment for a period of time, the relative clinical indicators of the experimental group and the control group were compared and analyzed.Results After the corresponding treatment, 3 patients in the experimental group had complications, the proportion was 12%, and 2 cases in the control group had adverse reactions, the incidence was 8%.The incidence of adverse reactions and the effectiveness of pain treatment in the experimental group were not significantly different from those in the control group, and there was no statistical significance.After treatment, the quality of life scores and general status scores of the experimental group and the control group were significantly higher than those before treatment, with statistical difference(P<0.05).There was no significant difference in the quality of life score and general condition score between the experimental group and the control group, and there was no statistical significance.Conclusion Zoledronic acid monotherapy in the treatment of metastasis corresponds largely to pamidronate treatment for lung cancer patients with bone, can improve the treatment effect and quality of life in a large extent, help the patients to relieve pain, with further clinical promotion and application significance.
zoledronic acid monotherapybone metastasis in patients with lung cancerclinical effect
NETL
NSTL
万方数据
维普
